GlassScriptPhysician profile
Robert Frank Ulrich
NPI 1215982699
$13,378.07
in general payments reported to CMS, 2019-2025
69 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,254 · 2020: $3,187 · 2021: $3,582 · 2022: $3,207 · 2023: $120 · 2024: $28.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $148.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $1,061.54 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $879.78 | 2019-2022 | |
| Amgen INC. | $835.37 | 2019-2022 | |
| Emd Serono, INC. | $661.40 | 2019-2022 | |
| Abbvie INC. | $604.68 | 2019-2024 | Duopa, Botox |
| Ucb, INC. | $591.72 | 2019-2022 | |
| Upsher-Smith Laboratories LLC | $591.09 | 2019-2022 | |
| Genzyme Corporation | $526.65 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $477.43 | 2019-2022 | |
| Allergan, INC. | $464.39 | 2019-2022 | |
| Lilly USA, LLC | $397.21 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $340.23 | 2020-2022 | |
| Genentech USA, INC. | $301.67 | 2019-2022 | |
| Acorda Therapeutics, INC | $298.75 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $288.95 | 2019-2022 |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ulrich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.